AMGN vs GILD Comparison: AI Score, Valuation, Performance and Upside
Compare Amgen and Gilead Sciences by biosimilar defense, HIV franchise durability, obesity drug pipeline, dividend yield, and long-term value.
Use this Amgen vs Gilead Sciences comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
GILD holds the edge across 3 of 5 key metrics in this comparison. AMGN has delivered stronger 1-year price return (+19.75% vs +18.31%), though GILD has the better forward P/E setup (13.83x vs 15.62x for AMGN). On fundamentals, AMGN is growing revenue faster (5.80%), while GILD maintains the higher operating margin (39.28%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for GILD (+17.89%) than for AMGN (-2.64%).
| Metric | AMGN | GILD |
|---|---|---|
| AI score | 47.8 | 41.9 |
| AI rank | #617 | #960 |
| Latest close | $366.05 | $130.34 |
| 1M return | +6.19% | +4.38% |
| 6M return | +6.53% | +0.95% |
| 1Y return | +19.75% | +18.31% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | GILD |
|---|---|---|
| 1Y ago | $11.84K (+18.4%) started 2025-07-23 | $11.48K (+14.8%) started 2025-07-23 |
| 5Y ago | $19.44K (+94.4%) started 2021-07-26 | $25.83K (+158.3%) started 2021-07-26 |
| 10Y ago | $39.04K (+290.4%) started 2016-07-25 | $29.6K (+196.0%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | GILD |
|---|---|---|
| Market cap | $197.69B | $166.72B |
| Trailing P/E | 25.51 | 18.27 |
| Forward P/E | 15.62 | 13.83 |
| Price/Sales | 4.57 | 4.87 |
| EV/Revenue | 6.53 | 6.02 |
| Analyst target | $356.62 | $158.30 |
| Target upside | -2.64% | +17.89% |
| Metric | AMGN | GILD |
|---|---|---|
| Revenue growth | 5.80% | 4.40% |
| Earnings growth | 4.40% | 54.80% |
| EPS growth | +4.40% | +54.80% |
| FCF margin | +19.98% | +26.68% |
| Operating margin | 33.80% | 39.28% |
| Profit margin | 20.96% | 30.99% |
| ROIC proxy | 101.32% | 43.36% |
| Return on equity | 101.32% | 43.36% |
| Dividend yield | 2.75% | 2.44% |
| Beta | 0.40 | 0.34 |
| Debt/equity | 623.75 | 94.64 |
| Current ratio | 1.26 | 1.97 |
| Quick ratio | 0.85 | 1.54 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | GILD |
|---|---|---|---|
| 1Y | Growth | +18.38% | +14.78% |
| CAGR | +18.43% | +14.82% | |
| Sharpe ratio | 0.59 | 0.48 | |
| Max drawdown | 16.57% | 22.03% | |
| Max daily drop | 5.14% | 3.72% | |
| Max wkly drop | 8.70% | 5.98% | |
| 5Y | Growth | +69.73% | +120.20% |
| CAGR | +11.18% | +17.13% | |
| Sharpe ratio | 0.37 | 0.59 | |
| Max drawdown | 24.86% | 26.59% | |
| Max daily drop | 7.14% | 10.15% | |
| Max wkly drop | 12.81% | 9.78% | |
| 10Y | Growth | +187.48% | +102.98% |
| CAGR | +11.15% | +7.34% | |
| Sharpe ratio | 0.37 | 0.23 | |
| Max drawdown | 24.86% | 30.47% | |
| Max daily drop | 9.58% | 10.15% | |
| Max wkly drop | 15.79% | 12.29% |
| Category | AMGN | GILD |
|---|---|---|
| Company | AMGN | GILD |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.